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ABSTRACT
Ulcerative colitis (UC) is a chronic
inflammatory bowel disease that has
significant morbidities in the pediatric
population. Goals of medical therapy include
induction and maintenance of remission while
preserving the colon and it’s function, while
minimizing the risk of treatment related
morbidities. For those children who do not
respond to initial therapies and progress to
develop moderately-to-severely active UC, there
has been a dearth of available treatments to
help induce remission, necessitating long-term
corticosteroid usage, with associated
comorbidities of chronic steroid treatment.
Significant advances have been made in
medical management, including the use of
biologic therapies, specifically anti-tumor
necrosis factor-a monoclonal antibodies. With
the Food and Drug Administration’s recent
approval of the use of infliximab, a chimeric
anti-tumor necrosis factor-a antibody, for
children C6 years of age with moderately-to-
severely active UC, care providers now have a
new treatment regimen to offer this pediatric
population.
Keywords: Gastroenterology; Infliximab;
Pediatric; Tumor necrosis factor-a; Ulcerative
colitis
INTRODUCTION
Ulcerative colitis (UC), along with Crohn’s
disease (CD) and inflammatory bowel disease
undetermined type (IBDU) make up the
spectrum of inflammatory bowel diseases
(IBD). IBD affects thousands of children
worldwide [1–4]. The highest incidence occurs
in developed industrialized countries, with 2–7
children per 100,000 becoming affected each
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year in the USA [3, 5]. IBD is a destructive
chronic inflammatory condition of the
gastrointestinal (GI) tract, and thus far the
etiology remains poorly understood, although
numerous studies point to a combination of
genetic, environmental, and host factors.
Current hypotheses of the pathogenesis of IBD
suggest that pathogenic or normal enteric flora
provide antigenic stimulation leading to a
dysregulated immune response in genetically
susceptible individuals with multiple potential
environmental predisposing factors causing
tissue damage and disease pathology [6–9]. In
this review, the authors will discuss current
therapies in pediatric UC, with a focus on the
indications for and the use of infliximab in
treating children with moderately-to-severely
active UC.
PATHOPHYSIOLOGY OF UC
While much of the etiology of IBD remains
undetermined, the altered balance between
enteric flora and the intestinal immune
response in genetically susceptible individuals
has been well described [10, 11]. Luminal
antigens interact with the mucosa normally,
yet with increased permeability one sees
triggering of multiple inflammatory pathways,
including the innate and adaptive immune
systems [12]. In UC, in response to bacterial
lipopolysaccharides, the T helper 2 (Th2)
response produces cytokines, interleukin (IL)-5,
and IL-13, as well as other proinflammatory
cytokines, which induce macrophages,
monocytes, neutrophils, T cells, and natural
killer (NK) cells to secrete tumor necrosis factor-
a (TNF-a), IL-1, and IL-6 [10, 11, 13]. TNF-a
activates leukocytes, induces acute phase
reactants, and inhibits apoptosis of
inflammatory cells, and can be found in
significant amounts in the mucosa of patients
with active UC [14]. Leukocytes migrate into
the mucosa, and release proteases, nitric
oxide, prostaglandins, free oxygen radicals,
endopeptidases, and chemokines which both
directly damage tissue and further amplify the
inflammatory process [11]. Understanding the
etiology of UC has guided the development of
treatment for the disease and the approach to
this illness.
The complex dysregulated immune response
along with severe inflammation lead to the key
feature of UC: diffuse superficial mucosal
inflammation extending proximally from the
rectum to varying locations [10]. The affected
area of the colon is variable and can affect
anywhere from the distal sigmoid alone, to
pancolitis. As compared with adults, the
pediatric UC population tend to present with
more extensive colonic involvement and more
commonly present with moderate-to-severe
disease activity [15].
Pediatric UC patients commonly present
with hematochezia, diarrhea, and abdominal
pain. Diagnostic evaluation consists of a
detailed history, physical exam, laboratory
data, small bowel imaging, upper GI
endoscopy, and colonoscopy. While pediatric
UC is limited to colonic inflammation, upper
endoscopy is key in evaluating for signs of CD.
Histologic findings are essential in confirming
the diagnosis of UC, and include colonic
mucosal inflammation, crypt distortion, crypt
microabscesses, and goblet cell depletion [16].
Role of TNF-a in UC
TNF-a, produced by activated macrophages and
T lymphocytes, is a key proinflammatory
cytokine in IBD. TNF-a has multiple actions,
including: (1) inducing many other
proinflammatory cytokines, including IL-1, IL-6,
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and IL-8; (2) enhancing leukocyte migration by
increasing expression of adhesion molecules by
endothelial cells; (3) activating leukocytes; (4)
inhibiting inflammatory cell apoptosis; and (5)
inhibiting regulatory macrophages which have
suppressive effects on the immune system,
including inhibiting the proliferation of
activated T cells [17–19]. TNF-a has been
found in increased amounts in the mucosa of
patients with UC [14].
Clinical Scoring of UC
Defining the severity of disease activity is
imperative in determining a treatment
approach. The moderate-to-severe phenotype
is a common presentation in children, with
[80% of children presenting with macroscopic
inflammation beyond the splenic flexure, as
compared to less than half of adults with disease
limited to the rectosigmoid [20]. While there is
a paucity of data on the frequency of severe UC
exacerbation in children, reported data on the
prevalence of severe UC at diagnosis varies from
15 to 57%. In pediatrics, use of the validated
Pediatric Ulcerative Colitis Activity Index
(PUCAI) based on clinical symptom reporting,
is useful in stratifying disease severity, in which
a PUCAI score of at least 65 was highly
associated with physician global assessment of
severe disease (sensitivity 92%, specificity 94%)
[21, 22]. Prospective data has supported the use
of PUCAI scoring in helping gauge treatment
decisions. Using this system, approximately
one-third of children with moderate-to-severe
PUCAI scores requiring hospital admission and
intravenous (IV) steroids will fail IV steroids,
and go on to require more intensive therapies.
Of those children who responded to IV steroids,
most responded within 6 days of therapy [23].
At this time, accepted definitions of
moderate-to-severe colitis can be determined
by using a combination of clinical history,
exam, need for hospitalization, and PUCAI
scoring, in which a score of moderate (35–64
points) or severe (C65 points), and response to
IV steroid therapy, where PUCAI scores on day 3
and 5 of treatment can be predictive of
treatment failure. If PUCAI scores do not
improve ([45 points) by day 3 of therapy,
discussions surrounding second-line therapy
should be initiated [24].
CURRENT THERAPIES
Treatment paradigms for UC have centered on
inducing and maintaining disease remission, in
order to improve clinical symptoms and
promote mucosal healing, thus promoting
improved growth, nutrition, and quality of
life. Various diagnostic and treatment
algorithms have been developed from the
assessment and treatment of UC, although it
remains medically incurable. There is a general
paucity of evidence in treating children with
IBD, thus many treatment modalities have been
based on adult data [25]. Inducing remission is
initiated with a combination of anti-
inflammatory medications and possibly
corticosteroids, with the goal of minimizing
medication use and steroid exposure [26].
Treatment focuses on addressing disease
severity and initiating the corresponding
agent to appropriately treat symptoms while
avoiding adverse reactions associated with
other therapies. Treatment options are
varied, including 5-aminosalicylates (5-ASA),
corticosteroids, 6-mercaptopurine (6-MP),
antibiotics, surgery, and most recently, anti-
TNF-a monoclonal antibody therapy. Therapies
used prior to the introduction of anti-TNF-a
(discussed in detail in the following section),
left an unmet need for those with more severe
disease. Anti-TNF-a monoclonal antibodies
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have helped to address the unmet medical need
in patients with moderate-to-severe UC who are
steroid-resistant or dependent and in whom
immuno modulators are not successful in
achieving remission.
Dosing and treatment approach in using
these myriads of medications is varied and
there is significantly less data to support the
use of these therapies in children as compared
to adults. There are strong data to support the
use of 5-ASA as initial therapy in mild-to-
moderate UC [27]. The mechanism of action
of 5-ASA remains unclear, although the primary
effect is considered to be an anti-inflammatory
effect directly on the mucosa, and as such is
available in multiple formulations, including
oral and rectal preparations (for more direct
administration of disease limited to proctitis or
distal left-sided disease) [28, 29]. While there
have been minimal data on inducing and
maintaining remission in pediatric UC, the
data are strong in adult UC for both inducing
remission, with number needed to treat
estimated at 5, with 40% of patients achieving
disease remission versus 20% with placebo, as
well as preventing relapse, with 40% of patients
on 5-ASA therapies relapsing versus 63%
relapsing on placebo [25, 30].
Corticosteroid therapy has been a mainstay
of treatment of UC and symptomatic
management, although it has been well
established that corticosteroids do not
promote mucosal healing [31, 32]. However,
up to a third of children with UC will require
corticosteroids to achieve disease remission at
the time of diagnosis, one-fifth will become
steroid dependent, and an additional one-third
will require surgery [33]. In patients with no or
partial response to oral, rectal, or topical
corticosteroids, treatment often escalates to
inpatient admission and IV steroid therapy
[28, 33, 34]. As noted above, in those who fail
IV steroid therapy, second-line therapy must be
considered. In adults, both IV cyclosporine and
oral tacrolimus have also been shown to be
effective at inducing remission in IV steroid
failure [35–38]. The use of IV cyclosporine has
not been as successful in small pediatric cohort
studies, which demonstrated short benefit with
the use of cyclosporine with successful delay of
colectomy of 81% of patients in the acute
period, but only 39% avoided colectomy at
long-term follow-up; and thus with its
significant side effect profile including
nephrotoxicity, it is not indicated in
maintaining remission [24, 39].
The role of immunomodulators, including
6-MP and its prodrug azathioprine, has been
indicated in maintaining remission of disease. In
a prospective cohort study, at 12-month follow-
up of 133 patients receiving a thiopurine
immunomodulator, 49% had steroid-free
inactive disease without the need for escalating
therapies, and an additional 10% had steroid-free
mild disease [40]. The use of these therapies must
be closely monitored, including a thiopurine
methyltransferase (TPMT) enzyme level, which
metabolizes 6-MP to its active metabolites
6-thioguanine nucleotide (6-TGN) and
6-methylmercaptopurine (6-MMP), where
increased levels of 6-TGN have been associated
with a favorable therapeutic response, and
increased levels of 6-MMP have been
associated with increased hepatotoxicity.
Indeed, the adverse reactions associated with
immunomodulators, including allergic
reactions, myelosuppression, hepatotoxicity,
and malignancy (including lymphoma) have
been well described as both dose dependent
effects (myelosuppression, hepatotoxicity) as
well as idiosyncratic, regardless of treatment
dosing [41].
Surgical therapy remains the only potentially
curative treatment in UC, and is considered a
4 Biol Ther (2013) 3:1–14
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final option for recalcitrant cases that fail
higher-tier medical therapies. Indications for
emergent surgical therapy include those
patients who present with severe
symptomatology, including perforation,
persistent bleeding, anemia, and toxic
megacolon [42]. Elective surgery should be
considered in those with refractory disease,
signs of colonic dysplasia or rectal cancer, or
those who chose to decline biologic therapy
[43]. The most widely accepted surgical
technique includes a total proctocolectomy
with ileal j-pouch anal anastomosis, generally
staged with a temporizing diverting ileostomy.
Surgery is not without complications, including
increased risks of pouchitis, increased stooling
frequency, incontinence, reduced fertility, need
for surgical revision or reoperation, and pouch
failure. Reported failure rates in adults range
from 6.8 to 8.5% at 36–60 months post
colectomy [44]. Although surgical intervention
can be potentially curative for UC, achieving
sustained clinical remission while preserving
the colon is the optimal successful outcome.
Anti-TNF-a antibody agents offer an
opportunity to avoid colectomy.
INFLIXIMAB
Infliximab is a chimeric murine-human
monoclonal immunoglobulin G1 antibody
composed of a murine variable region linked
to a human constant region, and is produced by
cell culture using Chinese hamster ovary cells
[45–47]. Infliximab is administered IV and
remains in the extracellular fluid, binding to
human TNF-a with high affinity and inducing
apoptosis of T cells and monocytes [48]. It has
an approximate half-life of 10 days and with a
single 5 mg/kg dose, levels are no longer
detectable (\0.1 lg/mL) by 12 weeks
postinfusion. The effect on inflammatory
cytokines can be rapid, with normalization of
IL-6 levels within 2 weeks of therapy [46, 49].
The Use of Infliximab in Treating UC:
Adult Data
Data on infliximab’s use in adult UC came
shortly after the US Food and Drug
Administration (FDA) approval of infliximab
for CD in 1998. To date, there have been five
randomized control trials (RCT) reporting
efficacy of biologic therapies in inducing
remission in adult patients with moderately-
to-severely active UC who failed corticosteroid
therapy. The first combined trials, the Active
Ulcerative Colitis Trials 1 and 2 (ACT 1 and
ACT 2, respectively), evaluated the efficacy of
infliximab in 364 adults with moderately-to-
severely active UC versus placebo, in which
patients had infliximab induction and
maintenance therapy with longitudinal follow-
up, where ACT 1 treated patients for 46 weeks
with a total follow-up of 54 weeks, and ACT 2
treated and followed patients for a shorter
duration (22 weeks of treatment, 30-week
follow-up). Patients were followed by clinical
symptoms, physician global assessment, and
endoscopic findings, and in both studies those
receiving infliximab had significant clinical
responses to treatment as compared to placebo
with 61.5–69.4% clinical improvement or
remission versus 37% in ACT 1, with similar
rates in ACT 2. Longitudinal follow-up also
showed a significantly higher sustained
response in the treatment subjects of both
studies. Importantly, mucosal healing at weeks
8, 30, and 54 (week 54 data from ACT 1 only)
demonstrated significantly more patients with
healing in the infliximab group [50].
In pooled data of adult RCTs of 827 patients
in the inpatient and ambulatory setting,
remission was achieved in over half the
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patients receiving infliximab (57.1%) as
compared to one-third of patients in the
placebo cohort. Infliximab was also found to
be efficacious, with a number needed to treat of
4 to achieve remission in one patient with
moderately-to-severely active UC (95%
confidence interval [CI], 3–8) [50–54].
Although the ACT 1 and ACT 2 trials followed
patients beyond the course of therapy, there
have been no RCTs examining the use of
biological therapies versus placebo in
preventing relapse in quiescent UC [51].
The Use of Infliximab in Treating UC:
Pediatric Data
Since the early 2000s, there has been a growing
body of data based on open label use of
infliximab to support its use in treating the
pediatric population with moderate-to-severe
UC. Here, the authors review the data leading to
the FDA’s approval of infliximab for use in
pediatric UC in September 2011. Data for this
review is derived from PubMed listed literature
describing both retrospective and prospective
studies of infliximab use in children \18 years
of age with UC. The authors excluded literature
from single case reports or case series.
Overall, the data have been supportive for the
use of infliximab in the pediatric UC population
for improving clinical symptoms and for some,
achieving disease remission, with evidence of
endoscopic healing [55–64]. Seminal studies
addressing the use of infliximab for the
treatment of UC are summarized in Table 1
[56–64]. This was initially found as part of
treating a generalized cohort of pediatric
patients with IBD [55]. In 2002 and 2004,
Mamula et al. [56, 57] reported on a larger
cohort of children with UC who were
persistently symptomatic after 2 weeks of
corticosteroids (nine patients in total), all of
whom had pancolitis at the initiation of
therapy. Seven patients demonstrated
significant clinical improvement after just
2 weeks of therapy, and of these seven patients,
six had improved to clinically inactive disease.
For those whom infliximab did not induce
improvement, one went on to colectomy, and
the other resumed corticosteroid therapy [56].
In longitudinal follow-up of this cohort, of the
original seven patients with clinical response,
five achieved sustained remission (including
three subjects who maintained remission after
discontinuation of therapy for up to 22 months
at the time of data collection), while two
went on to colectomy. They gained eight new
subjects in the interim, seven of whom had
also experienced clinical improvement on
infliximab [57].
Russell and Katz [58] performed a
retrospective cohort study, and noted that
when stratifying children with moderately-to-
severely active UC, children who were newly
diagnosed or who relapsed off steroids tended to
respond to infliximab, while those who were
steroid dependent did not have as strong a
clinical response. This retrospective review was
limited by small cohort sizes [58]. Follow-up
data from the same investigators in 27 patients
stratified by acute or chronic disease again
found higher rates of success in achieving
disease remission in those with acute disease
versus chronic disease (75% vs. 27%,
respectively) [60]. This was not corroborated in
the data presented by Eidelwein et al. [59], in
which a cohort of 12 patients, including those
with steroid-refractory fulminant colitis (n = 3)
and steroid dependent colitis (n = 9) received
infliximab, and all patients responded (three
patients partially, nine patients with complete
remission).
With the promising data on infliximab,
larger cohort studies have further supported its
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use for this refractory population. McGinnis
and Murray [65] published on a large cohort of
40 patients, using the adult clinical scoring
system by Truelove and Witt [66], in which they
demonstrated that 70% of patients with
moderate-to-severe UC identified clinical
response and, importantly, that at long-term
follow-up (median 19 months) those who
initially responded to infliximab had much
lower rates of colectomy versus those who did
not respond (20% colectomy rate vs. 82%)
[65, 66].
Cucchiara et al. [61] had a larger cohort of
patients maintained on infliximab beyond the
initial induction phase of 6–8 weeks. In their
cohort of 22 patients, 12 patients acutely
responded to infliximab, eight of whom went
on to receive infliximab routinely every
8 weeks, while the remaining four went on to
receive azathioprine alone. Follow-up at
54 weeks found that both groups remained in
clinical remission [61]. These findings warrant
further examination for the clinical utility in
infliximab maintaining remission, for which
data is lacking in both adult and pediatric
populations [30].
Hyams et al. [63] corroborated the above
data with data from the Pediatric Inflammatory
Bowel Disease Collaborative Research Group
Registry, a multicenter consortium of 21 IBD
centers in the United States and Canada. In
their cohort of 52 patients, a majority of which
had moderately-to-severely active UC (84%), a
significant proportion responded to infliximab
(36% with inactive disease, 19% with mild
disease after treatment), although a portion of
those patients remained on corticosteroids; as
to whether these were being tapered or
maintained for disease activity is unknown.
On longitudinal follow-up, those who
remained with inactive and mild disease
decreased to 21 and 11%, respectively, with a
cumulative colectomy rate of 16. It is difficult to
extrapolate whether this loss of sustained
response was secondary to infliximab, as a
majority of patients remained on infliximab
therapies for varying lengths of time [63].
Longitudinal use of infliximab was more
clearly studied in patients with a response to
acute infliximab therapy (44 of 60 patients) who
were randomized to receive infliximab every 8
or 12 weeks. Follow-up at 54 weeks indicated
that there were more subjects in remission in
the cohort who received infliximab every
8 weeks (8 of 22 patients) versus 12-week
dosing (4 of 22 patients), with an overall
remission rate of 28.6% [64]. These data were
supported by Turner et al., who noted that in a
cohort of 33 patients who received infliximab,
at 1-year follow-up, 52% of those who initially
responded to infliximab remained in remission
[23].
Taken together, the available pediatric
literature supports the use of anti-TNF-a
medications in the treatment of UC. Most
recently, this data was supported by
Consensus Guidelines for the Management of
Pediatric Ulcerative Colitis by the European
Crohn’s and Colitis Organization (ECCO) and
the European Society for Paediatric
Gastroenterology, Hepatology and Nutrition
(ESPGHAN) [67]. In fact, in 2011, the FDA
approved infliximab for the treatment of
moderately-to-severely active UC in children
[6 years of age in the setting of inadequate
response to conventional therapy. The
infliximab dose used in pediatric patients is
5 mg/kg. Similar to the adult population, IV
infusions are given at 0, 2, and 6 weeks for
induction. Infusions are then administered
every 8 weeks for maintenance of remission.
However, when there is inadequate response,
especially in the setting of sub therapeutic
infliximab trough levels, the dosage may be
8 Biol Ther (2013) 3:1–14
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increased (up to 10 mg/kg) or the dosing
interval may be decreased.
Immunogenicity of Infliximab
A well-described phenomenon in the use of
monoclonal antibody therapy is the antigenic
potential of the antibody to elicit a host
immune response against the treatment,
known as immunogenicity. In the case of
infliximab, this potential for developing
human anti chimeric antibodies (HACA) and
thereby having accelerated degradation of
infliximab is a potential explanation for those
who develop a loss of therapeutic response, lack
of response, and infusion reactions [68–70].
Giving regularly scheduled dosing and the
concomitant use of immunomodulators can
help ameliorate this response [68, 71]. There is
a commercially available test, AnserTM IFX
(Prometheus Laboratories Inc., San Diego, CA,
USA) that can measure both HACA levels and
infliximab levels, and can be drawn at any time
during the therapeutic regimen, although
currently this is not widely in use in clinical
practice.
Adverse Reactions with Infliximab
Therapy
Potential issues regarding the blocking of TNF-a
can include severe opportunistic infections,
malignancy, severe anaphylaxis, and mortality
[72]. In ACT 1 and ACT 2, no statistically
significant difference was found in patients
experiencing infusion reactions or other
common adverse effects, including headache,
rash, or arthralgia [50–54]. A recent review by
Lichtenstein et al. [72] on adult data noted an
increased risk of any infection (50.1% vs. 36.3%
in placebo, P\0.001), but no difference in the
frequency of serious infection (5.4% vs. 2.4%,
P = 0.085), with no difference in the risk of
infection if the patient was concomitantly on
an immunomodulator. There was no difference
in the risk of malignancy or mortality [72]. In a
small single center study from Finland (n = 23),
adverse reaction rates were reported as
26%, including abscess at infusion site,
anaphylaxis, urticaria, dizziness, and nausea,
chest pain, and severe sepsis with multifocal
leukoencephalopathy in a 16-year-old
male which resolved within 6 months of
discontinuation of therapy [73]. However, in
the aforementioned studies, only two patients
were reported as having to discontinue therapy,
a minority requiring treatment with
acetaminophen and diphenhydramine and a
minority with transient symptoms of flushing,
dizziness, pruritis, and tachycardia which
resolved spontaneously [56–60]. Two reported
patients required antibiotics; one received oral
therapy for an upper respiratory infection, the
other required IV antibiotic therapy for a local
cellulitis at the injection site [65].
Finally, concerns have been raised regarding
increased risks of malignancies in children on
anti-TNF-a therapy, including leukemia,
Hodgkin’s and non-Hodgkin’s lymphoma,
hepatosplenic T cell lymphoma (HSTCL),
melanoma, and solid organ tumors, with 48
cases reported from a database search of the
FDA’s Adverse Event Reporting System [74].
Upon further investigation of risk factors
associated with developing HSTCL, it was
mainly associated with young males who had
been exposed to both anti-TNF-a antibody
therapy and thiopurine immunomodulators
[75]. The authors did not find any association
with HSTCL in patients who had received anti-
TNF-a antibody therapy alone, implying that
TNF-a blockade alone may be necessary but not
sufficient to lead to malignancy. At this time,
there does appear to be an increased risk of
Biol Ther (2013) 3:1–14 9
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malignancy associated with anti-TNF-a therapy
but the low incidence reported does not
preclude the use of this therapy for treating
IBD; however, the body of data continues to
grow.
Based on adult and pediatric data, while the
use of infliximab must be monitored carefully
for risks of infusion reactions or anaphylaxis
and possible infection, overall it appears to be a
safe therapy for use in the pediatric population.
OTHER ANTI-TNF-A AGENTS
There are currently multiple other anti-TNF-a
agents on the market for the treatment of CD.
Two of these include adalimumab, a fully human
monoclonal antibody against TNF-a and
certolizumab pegol, a pegylated Fab fragment of
a humanized anti-TNF-a monoclonal antibody.
While there is no current randomized, controlled
pediatric trial in the treatment of UC with either
biologic therapy, there are adult studies on the
use of adalimumab, although it is currently not
FDA approved for this indication. Sandborn et al.
[76] evaluated the efficacy of adalimumab in
adult patients with UC. In a controlled and
double-blinded study they found adalimumab to
be safe and more effective than placebo for the
induction and maintenance of remission in
patients with moderate-to-severe UC refractory
to conventional therapy. There is one small,
retrospective study of ten pediatric patients with
IBD treated with adalimumab due to a lack or loss
of response to infliximab. In this study, three
patients with UC achieved improvement in the
short term [77]. However, one of these patients
later failed adalimumab treatment and required
colectomy. This study included a very small
number of UC subjects and larger studies are
required to determine the efficacy of adalimumab
in pediatric UC. There is promising data on
adalimumab’s use in pediatric Crohn’s disease for
patients with refractory disease, with loss of
response or an adverse reaction to infliximab,
with clinical remission rates reported between 22
and 42% [78, 79]. To date, there are no reports on
the use of certolizumab pegol in the treatment of
pediatric UC.
CONCLUSION
Infliximab has now been in use for over 10 years
as therapy in IBD and the supporting body of
data for its use in the pediatric population
continues to grow.
While nonbiologic therapies for pediatric UC
have been successful in managing children with
mild disease, there has been a dearth of
nonsurgical options to offer families.
Infliximab is a promising option, and the
authors encourage care providers to consider
this in treating children with moderate-to-
severe UC who are refractory to nonbiologic
therapies and potentially delaying surgical
intervention. With the FDA approval of
infliximab use in UC in children [6 years of
age, the authors hope the supporting evidence
will continue to grow. At this time, the use of
infliximab should be reserved for patients with
moderately-to-severely active colitis that are
either steroid dependent or resistant.
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